Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: Are they different from those in neoadjuvant concurrent chemoradiotherapy?

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Chong, Yousun ^a   Kim, Jae Hun ^a   Lee, Ho Yun ^a   Ahn, Yong Chan ^a   Lee, Kyung Soo ^a   Ahn, Myung Ju ^a   Kim, Jhingook ^a   Shim, Young Mog ^a   Han, Joungho ^a   Choi, Yoon La ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PACLITAXEL; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HISTOGRAM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTENSITY VARIABILITY; KURTOSIS; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MASS; PHYSICAL PARAMETERS; PREDICTION; PREOPERATIVE EVALUATION; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SIZE ZONE VARIABILITY; SKEWNESS; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; AGED; ANTAGONISTS AND INHIBITORS; LUNG NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84896258294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088598     Document Type: Article

References (39)

1. Ahn HK, Choi YL, Han JH, Ahn YC, Kim K, et al. (2013) Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. Lung Cancer 79: 300-306.
2. Park BB, Park JO, Kim H, Ahn YC, Choi YS, et al. (2006) Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer? Lung Cancer 53: 323-330. (Pubitemid 44189567)
3. Kozak MM, Murphy JD, Schipper ML, Donington JS, Zhou L, et al. (2011) Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol 6: 920-926.
4. Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, et al. (2012) A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer 118: 6126-6135.
5. Vaidya M, Creach KM, Frye J, Dehdashti F, Bradley JD, et al. (2012) Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother Oncol 102: 239-245.
6. Aukema TS, Kappers I, Olmos RA, Codrington HE, van Tinteren H, et al. (2010) Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med 51: 1344-1348.
7. Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, et al. (2011) First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 22: 559-566.
8. Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, et al. (2007) Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56: 383-389. (Pubitemid 46679091)
9. O'Brien ME, Myerson JS, Coward JI, Puglisi M, Trani L, et al. (2012) A phase II study of (1)(8)F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks. Eur J Cancer 48: 68-74.
10. Schaake EE, Kappers I, Codrington HE, Valdes Olmos RA, Teertstra HJ, et al. (2012) Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol 30: 2731-2738.
11. Johnson CR, Thames HD, Huang DT, Schmidt-Ullrich RK (1995) The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys 33: 281-287.
12. Mayr NA, Taoka T, Yuh WT, Denning LM, Zhen WK, et al. (2002) Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 52: 14-22. (Pubitemid 34041563)
13. Hong JH, Chen MS, Lin FJ, Tang SG (1992) Prognostic assessment of tumor regression after external irradiation for cervical cancer. Int J Radiat Oncol Biol Phys 22: 913-917.
14. Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, et al. (2011) Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 261: 165-171.
15. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, et al. (2012) Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262: 708-718.
16. William WN, Jr., Pataer A, Kalhor N, Correa AM, Rice DC, et al. (2013) Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 8: 222-228.
17. Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, et al. (2010) A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16: 4647-4653.
18. Kang H, Lee HY, Lee KS, Kim JH (2012) Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol 13: 371-390.
19. Lee HY, Lee KS, Ahn MJ, Hwang HS, Lee JW, et al. (2011) New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer 73: 63-69.
20. Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, et al. (2010) Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J Radiol 11: 618-626.
21. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K (2012) Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 22: 796-802.
22. Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ (2012) Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology 264: 834-843.
23. de Hoop B, Gietema H, van de Vorst S, Murphy K, van Klaveren RJ, et al. (2010) Pulmonary ground-glass nodules: increase in mass as an early indicator of growth. Radiology 255: 199-206.
24. Lee HY, Jeong JY, Lee KS, Kim HJ, Han J, et al. (2012) Solitary pulmonary nodular lung adenocarcinoma: correlation of histopathologic scoring and patient survival with imaging biomarkers. Radiology 264: 884-893.
25. Chandarana H, Rosenkrantz AB, Mussi TC, Kim S, Ahmad AA, et al. (2012) Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer. Radiology 265: 790-798.
26. Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, et al. (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52: 369-378.
27. Thibault G, Fertil B, Navarro C, Pereira S, Cau P, et al. (2009) Texture indexes and gray level size zone matrix: application to cell nuclei classification. Pattern Recognition Inf Process: 140-145.
28. Lee HY, Lee HJ, Kim YT, Kang CH, Jang BG, et al. (2010) Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 5: 497-503.
29. Kadota K, Colovos C, Suzuki K, Rizk NP, Dunphy MP, et al. (2012) FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol 19: 3598-3605.
30. Lee HY, Jeong JY, Lee KS, Yi CA, Kim BT, et al. (2013) Histopathology of Lung Adenocarcinoma Based on New IASLC/ATS/ERS Classification: Prognostic Stratification With Functional and Metabolic Imaging Biomarkers. J Magn Reson Imaging.
31. Yoon HJ, Lee HY, Lee KS, Choi YL, Ahn MJ, et al. (2012) Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology 265: 939-948.
32. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC Cancer Staging Manual New York, NY: Springer.
33. Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, et al. (2009) ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 34: 17-41.
34. Kamal NS, Soria JC, Mendiboure J, Planchard D, Olaussen KA, et al. (2010) MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 16: 1206-1215.
35. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, et al. (2004) Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26: 173-182. (Pubitemid 38759943)
36. Win T, Miles K, Janes SM, Ganeshan B, Shastry M, et al. (2013) Tumor Heterogeneity as measured on the CT component of PET/CT Predicts Survival in Patients with Potentially Curable Non-Small Cell Lung Cancer. Clin Cancer Res.
37. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
38. Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, et al. (2013) Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 266: 326-336.
39. Alic L, van Vliet M, van Dijke CF, Eggermont AM, Veenland JF, et al. (2011) Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response? Phys Med Biol 56: 1601-1616.